BXP — Beximco Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- £171.75m
- £245.64m
- BDT39.27bn
- 93
- 97
- 70
- 99
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | BAS | BAS | BAS | BAS | BAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 934 | 635 | 675 | 1,169 | 1,136 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3,706 | 3,753 | 3,388 | 3,996 | 4,379 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13,264 | 13,049 | 13,771 | 18,419 | 20,876 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 34,057 | 35,241 | 36,531 | 42,379 | 42,808 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 49,214 | 50,119 | 52,246 | 66,148 | 69,157 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12,746 | 11,358 | 9,350 | 12,736 | 13,265 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 19,626 | 17,624 | 15,216 | 25,548 | 25,476 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Total Equity | 29,588 | 32,495 | 37,031 | 40,600 | 43,681 |
Total Liabilities & Shareholders' Equity | 49,214 | 50,119 | 52,246 | 66,148 | 69,157 |
Total Common Shares Outstanding |